Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Response Study of SAGE-324 for the Treatment of Essential Tremor

NCT05173012 is registered in ClinicalTrials.gov with Sage Therapeutics as lead sponsor.

NCT NCT05173012
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05173012 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Response Study of SAGE-324 for the Treatment of Essential Tremor
Lead sponsor
Sage Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
January 5, 2022
Completion date
May 16, 2024
Enrollment
146 (actual)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

essential tremor